← ANALYST RATINGS · TIPRANKS
Oculis Holding (OCS): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $36.00, the highest $45.00, the lowest $20.00. The average is +393.8% from the last price of $7.29.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $7.00−6.7% | Hold | −4.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $7.00−6.7% | Hold | −4.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $7.00−6.7% | Hold | −4.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $7.00−6.7% | Hold | −4.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $7.00−6.7% | Hold | −4.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | +2.9% | Reiterated | 14.10.26on TipRanks 20:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $32.00 | Buy | +339.0% | Reiterated | 12.10.26on TipRanks 09:06 | −5.5%next day −3.3% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $40.00 | Buy | +448.7% | Reiterated | 28.09.26on TipRanks 06:55 | −1.5%next day +1.0% · 5 days −6.7% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $26.00 → $39.00+50.0% | Buy | +435.0% | Reiterated | 18.09.26on TipRanks 06:15 | +1.5%next day −1.6% · 5 days −9.8% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $23.00 → $20.00−13.0% | Buy | +174.3% | Assigned | 14.08.26on TipRanks 07:55 | +1.1%next day +2.0% · 5 days +2.5% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $45.00 → $41.00−8.9% | Buy | +462.4% | Reiterated | 08.08.26on TipRanks Aug 5 16:45 | +2.7%next day +1.8% · 5 days +2.3% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $38.00 | Buy | +421.3% | Reiterated | 07.08.26on TipRanks 14:50 | +1.8%next day +0.7% · 5 days +1.7% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $45.00 | Buy | +517.3% | Reiterated | 06.08.26on TipRanks Aug 7 08:01 | +2.7%next day +1.8% · 5 days +2.3% | ↗ |
| Unknown Analyst | Leerink Partners | $50.00 → $40.00−20.0% | Buy | +448.7% | Reiterated | 02.06.26on TipRanks Jun 3 06:07 | −15.4%next day +7.6% · 5 days −7.7% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $49.00 → $38.00−22.4% | Buy | +421.3% | Reiterated | 01.06.26on TipRanks 14:20 | −36.4%next day −15.4% · 5 days −23.6% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $53.00 | Buy | +627.0% | Reiterated | 12.05.26on TipRanks 02:50 | −6.7%next day +2.6% · 5 days −7.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Oculis Holding
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $36.43 at a price of $8.34 (+336.8%); now: $36.43 at $7.29 (+399.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 14 | 13 | 15 | 9 | 10 |
| Buy | 7 | 5 | 3 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.48 (from $-0.58 to $-0.36). Last quarter: $-0.19.
Best top-analyst consensus in the sector · Healthcare
About Oculis Holding
- CEO: Riad Sherif
- Employees: 60
- Bahnhofstrasse 7, Zug, ZG, 6300, CH
- oculis.com
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗